Aytu BioPharma Stock Price, News & Analysis (NASDAQ:AYTU) $2.36 -0.16 (-6.35%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$2.29▼$2.5450-Day Range$1.55▼$3.3352-Week Range$1.38▼$4.88Volume35,229 shsAverage Volume50,112 shsMarket Capitalization$13.15 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Aytu BioPharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside111.9% Upside$5.00 Price TargetShort InterestHealthy11.25% of Float Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector405th out of 949 stocksPharmaceutical Preparations Industry185th out of 444 stocks 3.5 Analyst's Opinion Consensus RatingAytu BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Aytu BioPharma has a forecasted upside of 111.9% from its current price of $2.36.Amount of Analyst CoverageAytu BioPharma has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.25% of the float of Aytu BioPharma has been sold short.Short Interest Ratio / Days to CoverAytu BioPharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aytu BioPharma has recently decreased by 4.71%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAytu BioPharma does not currently pay a dividend.Dividend GrowthAytu BioPharma does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAytu BioPharma has received a 39.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Carbinoxamine", "Methylphenidate", and "Amphetamine" products. See details.Environmental SustainabilityThe Environmental Impact score for Aytu BioPharma is -2.45. Previous Next 2.7 News and Social Media Coverage News SentimentAytu BioPharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aytu BioPharma this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Aytu BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aytu BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.34% of the stock of Aytu BioPharma is held by insiders.Percentage Held by Institutions45.09% of the stock of Aytu BioPharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Aytu BioPharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aytu BioPharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAytu BioPharma has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aytu BioPharma Stock (NASDAQ:AYTU)Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.Read More AYTU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AYTU Stock News HeadlinesNovember 15, 2023 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call TranscriptNovember 14, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2024 First Quarter Financial ResultsNovember 29, 2023 | Edge On The Street (Ad)An Unusual Way to Invest in GoldMost financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines. November 14, 2023 | finance.yahoo.comAytu BioPharma Reports Fiscal 2024 First Quarter Financial ResultsNovember 13, 2023 | markets.businessinsider.comAytu BioPharma earnings: here's what to expectNovember 8, 2023 | finance.yahoo.comAytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive YearNovember 7, 2023 | finance.yahoo.comAytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023October 28, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval SupplementNovember 29, 2023 | Edge On The Street (Ad)An Unusual Way to Invest in GoldMost financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines. October 28, 2023 | markets.businessinsider.comAytu BioPharma: Strategic Manufacturing Transition and Financial Growth Bolster Buy RatingOctober 26, 2023 | finance.yahoo.comAytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval SupplementOctober 9, 2023 | finance.yahoo.comAytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023September 28, 2023 | finance.yahoo.comThere's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted RevenuesSeptember 28, 2023 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call TranscriptSeptember 27, 2023 | finance.yahoo.comAytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023September 26, 2023 | benzinga.comEarnings Outlook For Aytu BioPharmaSeptember 26, 2023 | markets.businessinsider.comAytu BioPharma earnings: here's what Wall Street expectsSeptember 22, 2023 | finance.yahoo.comAytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023September 13, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma to Present at LD Micro Main Event XVI ConferenceSeptember 13, 2023 | finance.yahoo.comAytu BioPharma to Present at LD Micro Main Event XVI ConferenceAugust 9, 2023 | msn.comMaxim Group Initiates Coverage of Aytu BioPharma (AYTU) with Buy RecommendationAugust 9, 2023 | finance.yahoo.comLoss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Expected To Breakeven In The Medium-TermJuly 31, 2023 | finance.yahoo.comAytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian AuthorityJuly 6, 2023 | msn.comAytu BioPharma (AYTU) Price Target Increased by 71.43% to 122.40June 14, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu to Participate in the Maxim Group Virtual Healthcare ConferenceJune 13, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-MarketJune 13, 2023 | finance.yahoo.comAytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-MarketSee More Headlines Receive AYTU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/27/2023Today11/29/2023Next Earnings (Estimated)2/20/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AYTU CUSIPN/A CIK1385818 Webaytubio.com Phone(720) 437-6580FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+111.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($6.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,050,000.00 Net Margins-24.03% Pretax Margin-24.03% Return on Equity-47.43% Return on Assets-13.45% Debt Debt-to-Equity Ratio0.46 Current Ratio1.08 Quick Ratio0.88 Sales & Book Value Annual Sales$107.40 million Price / Sales0.12 Cash Flow$0.93 per share Price / Cash Flow2.55 Book Value$5.78 per share Price / Book0.41Miscellaneous Outstanding Shares5,570,000Free Float5,326,000Market Cap$13.15 million OptionableNot Optionable Beta-0.86 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Joshua R. Disbrow (Age 48)Chairman & CEO Comp: $708kMr. Mark K. Oki CPA (Age 54)CFO, Secretary & Treasurer Comp: $522.84kMr. Greg Pyszczymuka (Age 44)Chief Commercial Officer Comp: $525kMs. Victoria CordovaVice President of People & CultureMr. Jarrett T. Disbrow Ph.D. (Age 48)Chief Business Officer & President of Consumer Health Comp: $355kMr. Russ McMahenSenior Vice President of Research & DevelopmentMr. Ryan J. Selhorn CPA (Age 41)Executive VP of Finance & Business Optimization More ExecutivesKey CompetitorsLipocineNASDAQ:LPCNMainz BiomedNASDAQ:MYNZGenprexNASDAQ:GNPXNanoViricidesNYSE:NNVCContext TherapeuticsNASDAQ:CNTXView All CompetitorsInsidersGreg PyszczymukaBought 12,000 shares on 6/16/2023Total: $22,440.00 ($1.87/share)Joshua R DisbrowBought 14,000 shares on 6/14/2023Total: $26,040.00 ($1.86/share)Joshua R DisbrowBought 112,371 shares on 12/19/2022Total: $24,721.62 ($0.22/share)Greg PyszczymukaBought 100,000 shares on 12/19/2022Total: $24,000.00 ($0.24/share)View All Insider Transactions AYTU Stock Analysis - Frequently Asked Questions Should I buy or sell Aytu BioPharma stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aytu BioPharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AYTU shares. View AYTU analyst ratings or view top-rated stocks. What is Aytu BioPharma's stock price target for 2024? 2 brokers have issued 12-month price objectives for Aytu BioPharma's stock. Their AYTU share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 111.9% from the stock's current price. View analysts price targets for AYTU or view top-rated stocks among Wall Street analysts. How have AYTU shares performed in 2023? Aytu BioPharma's stock was trading at $0.1890 at the start of the year. Since then, AYTU stock has increased by 1,148.7% and is now trading at $2.36. View the best growth stocks for 2023 here. When is Aytu BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024. View our AYTU earnings forecast. How were Aytu BioPharma's earnings last quarter? Aytu BioPharma, Inc. (NASDAQ:AYTU) issued its earnings results on Wednesday, September, 27th. The company reported $0.16 EPS for the quarter. The business earned $30.73 million during the quarter. Aytu BioPharma had a negative trailing twelve-month return on equity of 47.43% and a negative net margin of 24.03%. When did Aytu BioPharma's stock split? Aytu BioPharma shares reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Aytu BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioPharma investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX). Who are Aytu BioPharma's major shareholders? Aytu BioPharma's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armistice Capital, Llc, Greg Pyszczymuka and Joshua R Disbrow. View institutional ownership trends. How do I buy shares of Aytu BioPharma? Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AYTU) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.